Trade Editas Medicine - EDIT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023485% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001262% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.14 |
| Open | 1.11 |
| 1-Year Change | -84.98% |
| Day's Range | 1.1 - 1.15 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 1.14 | -0.06 | -5.00% | 1.20 | 1.20 | 1.13 |
| Mar 28, 2025 | 1.22 | -0.07 | -5.43% | 1.29 | 1.29 | 1.22 |
| Mar 27, 2025 | 1.27 | 0.01 | 0.79% | 1.26 | 1.29 | 1.23 |
| Mar 26, 2025 | 1.25 | -0.04 | -3.10% | 1.29 | 1.29 | 1.22 |
| Mar 25, 2025 | 1.28 | -0.09 | -6.57% | 1.37 | 1.37 | 1.26 |
| Mar 24, 2025 | 1.36 | 0.04 | 3.03% | 1.32 | 1.37 | 1.29 |
| Mar 21, 2025 | 1.28 | 0.00 | 0.00% | 1.28 | 1.31 | 1.24 |
| Mar 20, 2025 | 1.34 | 0.00 | 0.00% | 1.34 | 1.40 | 1.31 |
| Mar 19, 2025 | 1.38 | 0.07 | 5.34% | 1.31 | 1.38 | 1.29 |
| Mar 18, 2025 | 1.29 | -0.09 | -6.52% | 1.38 | 1.42 | 1.29 |
| Mar 17, 2025 | 1.38 | -0.03 | -2.13% | 1.41 | 1.43 | 1.29 |
| Mar 14, 2025 | 1.44 | 0.07 | 5.11% | 1.37 | 1.48 | 1.37 |
| Mar 13, 2025 | 1.34 | -0.14 | -9.46% | 1.48 | 1.54 | 1.34 |
| Mar 12, 2025 | 1.48 | 0.01 | 0.68% | 1.47 | 1.51 | 1.39 |
| Mar 11, 2025 | 1.45 | -0.07 | -4.61% | 1.52 | 1.54 | 1.34 |
| Mar 10, 2025 | 1.53 | -0.06 | -3.77% | 1.59 | 1.66 | 1.50 |
| Mar 7, 2025 | 1.70 | -0.06 | -3.41% | 1.76 | 1.80 | 1.65 |
| Mar 6, 2025 | 1.74 | -0.18 | -9.37% | 1.92 | 1.99 | 1.69 |
| Mar 5, 2025 | 2.02 | 0.24 | 13.48% | 1.78 | 2.22 | 1.78 |
| Mar 4, 2025 | 1.78 | 0.06 | 3.49% | 1.72 | 1.78 | 1.63 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Editas Medicine Company profile
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com